Results for 'European Medicines Agency'
Practical Advice for When You're Downsized. What Activities will Pay-off after a Lay-off?
Sep 15th • 5 mins read
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
Apr 20th • 8 mins read
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Apr 7th • 12 mins read
Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?
Feb 11th • 3 mins read
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
Mar 12th • 7 mins read
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
Feb 11th • 4 mins read
Safeguarding cancer research funding by European charities amidst the COVID-19 pandemic
Nov 22nd • 3 mins read
A Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma-To Know, Then to Measure
Aug 12th • 10 mins read
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
Sep 6th • 20 mins read
Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
Aug 31st • 16 mins read
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
Aug 16th • 8 mins read
Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives
Aug 7th • 10 mins read
Biosimilars in oncology: key role of nurses in patient education
Jun 15th • 10 mins read
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
May 21st • 8 mins read
Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis
Nov 24th • 10 mins read
Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015
Feb 23rd • 12 mins read